RethinkX is an independent not-for-profit research organization that analyzes and forecasts technology-driven disruptions. We do not focus on any one sector; our work spans energy, transportation, food, labor, and now healthcare. The foundation of our work, the Seba Technology Disruption Framework, is designed to identify the dynamics and implications of technological change wherever they occur.

Ultimately, the main reason RethinkX is talking about healthcare is because we see in Health Optimizer Therapies (HOTs) the same patterns we have seen in other major disruptions across economic sectors. We are a disruption research organization, not a healthcare company, a pharmaceutical company, or a medical advisory body. Our interest in GLP-1 drugs, myostatin and activin inhibitors and the HOTs category as a whole is economic and systemic.

We are focused on what happens to hospitals, food companies, insurance markets, agricultural sectors, criminal justice systems, geopolitical relationships, the environment etc. when a large fraction of the global adult population begins taking a class of drugs that makes them substantially healthier. These fundamental questions about disruption dynamics are precisely the domain where RethinkX operates.

Rethinking Health: The Health Optimizer Therapy (HOT) Disruption is therefore best understood not as a medical or clinical document (it carries an explicit disclaimer to that effect), but as a systemic analysis of a technology-driven transformation that will ripple through society and the economy in ways most observers have not yet fully reckoned with.

Explore the evidence...

• RethinkX applies the Seba Technology Disruption Framework to identify and forecast technology-driven disruptions across all sectors of the economy. Healthcare is not a special case, it is a sector undergoing a classic disruption pattern that the framework is specifically designed to analyze.
  
  
  • GLP-1 drugs display the same signature RethinkX has identified in every major disruption we have studied: decades of incremental improvement followed by a sudden threshold crossing into explosive adoption, cascading consequences across multiple industries, and incumbent resistance that proves futile. Learn more about how the disruption framework applies to HOTs in our Rethinking Health report.
  • RethinkX has previously applied this framework to transportation, energy, and food, in each case identifying disruptions that mainstream analysts underestimated in speed and scale. The HOT disruption follows the same pattern. Learn more about RethinkX's disruption research across sectors

• The questions RethinkX is focused on are systemic: what happens to hospitals, food companies, insurance markets, agricultural sectors, criminal justice systems, and geopolitical relationships when a large fraction of the global adult population becomes substantially healthier? These are disruption dynamics questions, and they are the core of what RethinkX does.
  • Learn more about the industry implications of the HOT disruption in our Rethinking Health report.
  • Learn more about the social, geopolitical, and environmental implications of the HOT disruption in our Rethinking Health report.
  
  
  
  

Witness the transformation

We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.

The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.

Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.

Learn more about the HOT disruption and its implications for health, society, and the economy.

Disclaimer

The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.